Atossa Therapeutics (NASDAQ:ATOS) Given New $7.00 Price Target at HC Wainwright

Atossa Therapeutics (NASDAQ:ATOS) had its price target raised by equities research analysts at HC Wainwright from $6.00 to $7.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 389.51% from the stock’s previous close.

Several other equities research analysts also recently commented on ATOS. Ascendiant Capital Markets upped their price target on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a research report on Wednesday, September 11th. StockNews.com cut shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 8th.

Atossa Therapeutics Stock Performance

NASDAQ ATOS traded down $0.07 on Wednesday, reaching $1.43. The company’s stock had a trading volume of 553,177 shares, compared to its average volume of 1,074,224. Atossa Therapeutics has a twelve month low of $0.63 and a twelve month high of $2.31. The firm’s 50 day moving average is $1.44 and its two-hundred day moving average is $1.38. The stock has a market cap of $179.84 million, a PE ratio of -6.81 and a beta of 1.23.

Atossa Therapeutics (NASDAQ:ATOS) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. Equities research analysts anticipate that Atossa Therapeutics will post -0.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Intech Investment Management LLC acquired a new position in Atossa Therapeutics in the third quarter worth approximately $29,000. XTX Topco Ltd bought a new position in Atossa Therapeutics in the second quarter valued at approximately $29,000. Cetera Advisors LLC bought a new position in Atossa Therapeutics during the first quarter worth about $72,000. SG Americas Securities LLC grew its position in Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after purchasing an additional 30,037 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in Atossa Therapeutics in the third quarter valued at approximately $75,000. 12.74% of the stock is owned by institutional investors and hedge funds.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.